This collaboration unites Parexel’s extensive expertise in global clinical research with TASK’s state-of-the-art infrastructure and operational excellence, providing innovative solutions for vaccine trials.
Through this partnership, we are poised to meet the increasing global need for innovative vaccine research solutions, by tapping into South Africa’s diverse population and advanced clinical trial sites. South Africa’s unique demographics, including a high prevalence of infectious diseases and a diverse genetic makeup, make it an ideal location for conducting vaccine trials that are representative of global populations.
Key benefits of this partnership include:
- In-depth scientific and regulatory knowledge
- Comprehensive experience in vaccine trials
- Seamless trial management from protocol design to execution
- Faster study timelines through optimized regulatory processes and efficient site start-ups
- Access to a network of top-tier investigators and world-class facilities
“We are honoured to join the Parexel Vaccine Network and bring our expertise to the development of critical vaccines,” said Johann de Bruyn, CEO of TASK. “This partnership reflects our commitment to delivering life-saving treatments to communities in South Africa and beyond.”